PUBLIC COMPANY
save$SUPNSUPERNUS PHARMACEUTICALS, INC.
$SUPN43.54-0.98%Rockville, MD, USupdated 23h ago
community read0 votes
pipeline
3
marketed
2
phase 3
0
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 22Marketed
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase4Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- phase3Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
- phase2Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
- phase4Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
- phase2Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- phase4Therapy for Migraine Prevention in Children 6-11 Years of Age
- phase3A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
- phase2Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
🐶 Hiring Signal
next earnings Nov 3, 2026
News
- Supernus and Indivior merge to create CNS mega-company with 11 approved drugsSupernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”biospace · 1mo ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that